Simulations Plus said this week that it has agreed to buy out a software royalty agreement it had with Enslein Research, a computational metabolism and toxicity prediction systems firm.
Previously, the firms shared revenues from the Enslein metabolism module, which is included in Simulations Plus' ADMET Predictor software. Under the terms of the new agreement, Simulations Plus paid $75,000 — equivalent to three years’ worth of royalties — to acquire the software IP from the Rochester, NY-based company.
Walt Woltosz, chairman and CEO of Simulations Plus, said that the company will amortize the purchase price over ten years, “so if sales continue at a similar or greater pace, we will realize lower annual expenses."
In January, Simulations reported a profit for the first quarter of its fiscal year alongside a 10 percent rise in revenues (BI 01/20/2012).
The new IP gives Simulations Plus a proprietary database of about 500 metabolism measurements that it will use to build predictions for the hydroxylation reactions caused by CYP450 enzymes, as well as around 900 compounds that it will use to build substrate classification models for UGT enzymes.
Additionally, "we will also now have a more convenient way to package our metabolism and metabolic site capabilities within ADMET Predictor, which were previously maintained as separate modules for tracking purposes,” Woltosz said.
Last November, Simulations sold Words+, its computer-based communications systems subsidiary so that it could focus on expanding its footprint in pharmaceutical markets (BI 11/18/2011).